TY - JOUR
T1 - The Half Century of Clinical Trials of the National Surgical Adjuvant Breast and Bowel Project
AU - Wickerham, D. Lawrence
AU - O'Connell, Michael J.
AU - Costantino, Joseph P.
AU - Cronin, Walter M.
AU - Paik, Soonmyung
AU - Geyer, Charles E.
AU - Ganz, Patricia A.
AU - Petrelli, Nicholas
AU - Mamounas, Eleftherios P.
AU - Julian, Thomas B.
AU - Wolmark, Norman
N1 - Funding Information:
Supported in part by National Cancer Institute Grants No. U10-CA37377, U10-CA69974, U10-CA69651, U10-CA12027, and U24-CA114732.
Funding Information:
Specific BAHO studies that have been completed or are still ongoing include the measurement of neurotoxicity in adjuvant therapy with oxaliplatin in colon cancer (NSABP C-07) 22,33 ; the assessment of arm function after sentinel node biopsy (NSABP B-32); the assessment of amenorrhea in association with adjuvant chemotherapy in breast cancer (NSABP B-30 and B-36); and the assessment of HRQOL in a comparison of different adjuvant treatment regimens (NSABP B-33, B-35, and B-36). We also have launched our first long-term survivor study (LTS-01, supported by an extramural grant from the American Cancer Society), which is examining late effects of treatments used in our R-02, R-03, C-05, C-06, and C-07 trials in colorectal cancer patients beyond 5 years after diagnosis.
PY - 2008/10
Y1 - 2008/10
N2 - The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the monoclonal antibody trastuzumab in women with HER2-positive breast cancer are all the direct results of research that has been carried out over the past 50 years by the National Surgical Adjuvant Breast and Bowel Project (NSABP). This National Cancer Institute-supported clinical cooperative trials group based in Pittsburgh, PA, currently has 200 member institutions and 700 satellite centers located throughout the United States, Canada, Puerto Rico, and Ireland. The NSABP's mandate is to conduct large randomized phase III trials to evaluate therapies designed to improve the treatment and prevention of breast and colorectal cancer. Over the past half century, the NSABP has entered more than 150,000 patients and participants into clinical studies that have changed the treatment of colorectal cancer and have revolutionized the treatment and prevention of breast cancer.
AB - The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the monoclonal antibody trastuzumab in women with HER2-positive breast cancer are all the direct results of research that has been carried out over the past 50 years by the National Surgical Adjuvant Breast and Bowel Project (NSABP). This National Cancer Institute-supported clinical cooperative trials group based in Pittsburgh, PA, currently has 200 member institutions and 700 satellite centers located throughout the United States, Canada, Puerto Rico, and Ireland. The NSABP's mandate is to conduct large randomized phase III trials to evaluate therapies designed to improve the treatment and prevention of breast and colorectal cancer. Over the past half century, the NSABP has entered more than 150,000 patients and participants into clinical studies that have changed the treatment of colorectal cancer and have revolutionized the treatment and prevention of breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=52949141386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52949141386&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2008.07.005
DO - 10.1053/j.seminoncol.2008.07.005
M3 - Article
C2 - 18929150
AN - SCOPUS:52949141386
SN - 0093-7754
VL - 35
SP - 522
EP - 529
JO - Seminars in oncology
JF - Seminars in oncology
IS - 5
ER -